medigraphic.com
ISSN 1684-1824 (Digital)

2012, Número 3

<< Anterior Siguiente >>

Rev Méd Electrón 2012; 34 (3)


Tumores astrocíticos: un acercamiento a una patología

Vega RAM, Rodríguez VMI, Wilkinson BB, Fernández LA

Idioma: Español
Referencias bibliográficas: 48
Paginas:
Archivo PDF: 167.80 Kb.


RESUMEN

El cáncer constituye un serio problema de salud para la humanidad. La mayoría de los tumores primarios del Sistema Nervioso Central son tumores astrocíticos. En esta revisión se provee información sobre algunos aspectos relacionados con los tumores astrocíticos, que incluyen la clasificación, factores pronóstico, tratamiento habitual, terapia biológica y factores angiogénicos. El glioblastoma multiforme se diagnostica en los pacientes con una mayor frecuencia. El tratamiento estándar en pacientes con tumores astrocíticos comprende la cirugía, seguida de radiación y quimioterapia. Sin embargo, cada vez son más importantes las investigaciones dirigidas a la inmunoterapia y terapia génica como parte de las opciones terapéuticas en estos pacientes.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10. PubMed; PMID: 19934210.

  2. Dirección Nacional de Registros Médicos y Estadística. Incidencia 2002. Mortalidad 2002/2004. En: Anuario Estadístico de Salud Pública 2004. La Habana: Ministerio de Salud Pública; 2005.

  3. Dirección Nacional de Registros Médicos y Estadística. Mortalidad. En: Anuario Estadístico de Salud 2008. La Habana: Ministerio de Salud Pública; 2009.

  4. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375-81. PubMed; PMID: 11389063.

  5. Libermann TA, Razon N, Bartal AD, Yarden Y, Schlessinger J, Soreq H. Expression of epidermal growth factor receptors in human brain tumors. Cancer Res [Internet]. 1984 [citado 12 Dic 2011];4:753-60. Disponible en: http://cancerres.aacrjournals.org/content/44/2/753.full.pdf+html.

  6. Steck PA, Lee P, Hung MC, Yung WKA. Expression of an altered epidermal growth factor receptor by human glioblastoma cells. Cancer Res [Internet]. 1988 [citado 12 Dic 2011];48(19):5433-9. Disponible en: http://cancerres.aacrjournals.org/content/48/19/5433.full.pdf+html.

  7. Van der Valk P, Lindeman J, Kamphorst W. Growth factors profiles of human gliomas. Do non-tumor cells contribute to tumor growth in glioma? Ann Oncol. 1997;8(10):1023-9. PubMed; PMID: 9402177.

  8. Ragel B, Jensen RL. New approaches for the treatment of refractory Meningiomas. Cancer Control. 2003;10:148-58. PubMed; PMID: 12712009.

  9. Feldkamp MM, Lala P, Lau N, Roncari L, Guha A. Expression of activated epidermal factor receptors, Ras-guanosine triphosphate, and mitogen activated protein kinase in human glioblastoma multiforme specimens. Neurosurgery. 1999;45(6):1442-3. PubMed; PMID: 10598712.

  10. Lorimer IA. Mutant epidermal growth factor receptors as targets for cancer therapy. Curr Cancer Drug Targets. 2002;2(2):91-102. PubMed; PMID: 12188912.

  11. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8(8):2725-34. PubMed; PMID: 12171906.

  12. Storstein A, Helseth E, Johannesen TB, Schellhorn T, Mørk S, Helvoirt RV. High-grade gliomas in adults. Tidsskr Nor Laegeforen. 2011;131(3):238-41. PubMed; PMID: 21304572.

  13. Nieder C, Mehta MP, Jalali R. Combined radio- and chemotherapy of brain tumours in adult patients. Clin Oncol (R Coll Radiol). 2009;21(7):515-24. PubMed; PMID: 19487112.

  14. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM et al. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008;10(2):162-70. PubMed; PMID: 18356283.

  15. Hickey MJ, Malone CC, Erickson KL, Jadus MR, Prins RM, Liau LM, et al. Cellular and vaccine therapeutic approaches for gliomas. J Transl Med. 2010; 8:100. PubMed; PMID: 20946667.

  16. Henriksson R, Asklund T, Poulsen HS. Impact of therapy on quality of life, neurocognitive function and their correlates in glioblastoma multiforme: a review. J Neurooncol. 2011;104(3):639-46. PubMed; PMID: 21468776.

  17. Ushio Y, Kochi M. Prognostic factors in malignant gliomas. Gan To Kagaku Ryoho. 1996;23(5):643-8. PubMed; PMID: 8678527.

  18. Chansriwong P, Sirisinha T. Clinical features, management and outcomes of high-grade glioma patients in Ramathibodi Hospital. J Med Assoc Thai. 2010;93(Suppl 2):S68-73. PubMed; PMID: 21299082.

  19. Kanamori M, Kumabe T, Saito R, Yamashita Y, Sonoda Y, Tominaga T. The safety of combination chemotherapy with ifosfamide, cisplatin, and etoposide (ICE): single-institution retrospective review of 108 cases. No Shinkei Geka. 2010;38(11):997-1005. PubMed; PMID: 21081811.

  20. Mizumatsu S, Tamiya T, Ono Y, Abe T, Matsumoto K, Furuta T, Ohmoto T. Expression of cell cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res. 1999;5(3):551-7. PubMed; PMID: 10100706.

  21. Zagzag D, Blanco C, Friedlander DR, Miller DC, Newcomb EW. Expression of p27KIP1 in human gliomas: relationship between tumor grade, proliferation index, and patient survival. Hum Pathol. 2003;34(1):48-53. PubMed; PMID: 12605366.

  22. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61(11):4375-81. PubMed; PMID: 11389063.

  23. Tamiya T, Mizumatsu S, Ono Y, Abe T, Matsumoto K, Furuta T, et al. High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol. 2001;101(4):334-40. PubMed; PMID: 11355304.

  24. Burton EC, Prados MD. Malignant gliomas. Curr Treat Options Oncol. 2000;1(5):459-68. PubMed; PMID: 12057153.

  25. Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Chemotherapy wafers for high grade glioma. Cochrane Database Syst Rev. 2011;3:CD007294. PubMed; PMID: 21412902.

  26. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG. Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment Glioma. AJNR Am J Neuroradiol. 2011 Mar 31. PubMed; PMID: 21393407.

  27. Dixit S, Hingorani M, Achawal S, Scott I. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg. 2011;25(4):459-69. PubMed; PMID: 21344976.

  28. Noël G, Schott R, Froelich S, Gaub MP, Boyer P, Fischer-Lokou D, et al. Retrospective Comparison of Chemoradiotherapy Followed by Adjuvant Chemotherapy, With or Without Prior Gliadel Implantation (Carmustine) After Initial Surgery in Patients With Newly Diagnosed High-Grade Gliomas. Int J Radiat Oncol Biol Phys. 2011;81(5):1593. PubMed; PMID: 22115561.

  29. McGirt MJ, Than KD, Weingart JD, Chaichana KL, Attenello FJ, Olivi A, et al. Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme. J Neurosurg. 2009;110(3):583-8. PubMed; PMID: 19046047.

  30. Garside R, Pitt M, Anderson R, Rogers G, Dyer M, Mealing S, et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol Assess. 2007;11(45):iii-iv, ix-221. PubMed; PMID: 17999840.

  31. Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8(8):2725-34. PubMed; PMID: 12171906.

  32. Rodríguez Vera L. Evaluación farmacocinética y toxicológica del AcM Nimotuzumab (hR3) administrado en combinación con Doxorrubicina y Ciclofosfamida en pacientes con cáncer de mama estadíos III [tesis]. Ciudad de La Habana: Universidad de La Habana, Instituto de Farmacia y Alimentos; 2006.

  33. Zustovich F, Lombardi G, Pastorelli D, Farina P, Furini L, Manara R, et al. Bevacizumab and glioblastomas, a single-centre experience: how disease history and characteristics may affect clinical outcome. Anticancer Res. 2010;30(12):5213-6. PubMed; PMID: 21187515.

  34. Crombet T, Figueredo J, Catala M, González S, Selva JC, Cruz TM, et al. Treatment of high-grade glioma patients with the humanized anti-EGFR MAb h-R3: report from a phase I/II trial. Cancer Biol Ther 2006; 5:375-9.

  35. Scott BJ, Quant EC, McNamara MB, Ryg PA, Batchelor TT, Wen PY. Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors. Neuro Oncol. 2010;12(6):603-7. PubMed; PMID: 20156808.

  36. Chow KK, Gottschalk S. Cellular immunotherapy for high-grade glioma. Immunotherapy. 2011;3(3):423-34. PubMed; PMID: 21395383.

  37. Virasch N, Kruse CA. Strategies using the immune system for therapy of brain tumors. Hematol Oncol Clin North Am. 2001;15(6):1053-71. PubMed; PMID: 11770298.

  38. Borghaei H, Smith MR, Campbell KS. Immunotherapy of cancer. Eur J Pharmacol. 2009;625(1-3):41-54. PubMed; PMID: 19837059.

  39. Herlyn D, Wettendorff M, Koprowski H. Modulation of cancer patients' immune responses by anti-idiotypic antibodies. Int Re Immunol. 1989;4(4):347-57. PubMed; PMID: 2519932.

  40. Schultes BC, Nicodemus CF. Using antibodies in tumour immunotherapy. Expert Opin Biol Ther. 2004;4(8):1265-84. PubMed; PMID: 15268661.

  41. Becker Y. Molecular immunological approaches to biotherapy of human cancers--a review, hypothesis and implications. Anticancer Res. 2006;26(2A):1113-34. PubMed; PMID: 16619514.

  42. Brekke OH, Sandlie I. Therapeutic antibodies for human diseases at the dawn of the twenty-first century. Nat Rev Drug Discov. 2003;2(1):52-62. PubMed; PMID: 12509759.

  43. Pittet MJ. Behavior of immune players in the tumor microenvironment. Curr Opin Oncol. 2009 Jan;21(1):53-9. PubMed; PMID: 19125019.

  44. Kundu JK, Surh YJ. Inflammation: Gearing the journey to cancer. Mutat Res. 2008;659(1-2):15-30. PubMed; PMID: 18485806.

  45. Sharma PS, Sharma R, Tyagi T. VEGF/VEGFR Pathway Inhibitors as Anti-Angiogenic Agents: Present and Future. Curr Cancer Drug Targets. 2011 Apr;11(5):624-53. PubMed; PMID: 21486218.

  46. Presta LG, Chen H, O'Connor SJ, Chisholm V, Meng YG, Krummen L, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res. 1997;57(20):4593-9. PubMed; PMID: 9377574.

  47. Folkerth RD. Descriptive analysis and quantification of angiogenesis in human brain tumors. J Neurooncol. 2000;50(1-2):165-72. PubMed; PMID: 11245275.

  48. Charles NA, Holland EC, Gilbertson R, Glass R, Kettenmann H. The brain tumor microenvironment. Glia. 2011 Mar;59(8):1169-80. PubMed; PMID: 21446047.




2020     |     www.medigraphic.com